z-logo
open-access-imgOpen Access
Overexpression miR‐211‐5p hinders the proliferation, migration, and invasion of thyroid tumor cells by downregulating SOX 11
Author(s) -
Wang Lei,
Shen Yanfeng,
Shi Zhimin,
Shang Xiaojuan,
Jin Dongling,
Xi Feng
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22293
Subject(s) - flow cytometry , cell growth , viability assay , apoptosis , mtt assay , cell cycle , reporter gene , cancer research , gentamicin protection assay , microbiology and biotechnology , cell culture , chemistry , biology , gene expression , gene , western blot , biochemistry , genetics
Purpose This study was aimed to investigate the relationship between miR‐211‐5p and SOX 11 , and the effects of their interaction on the proliferation, viability, and invasion of human thyroid cancer ( TC ) cells. Methods We used quantitative real‐time PCR ( qRT ‐ PCR ) to determine the expression of miR‐211‐5p and SOX 11 mRNA in the thyroid tumorous and the adjacent tissues. The target relationship between miR‐211‐5p and SOX 11 was confirmed using dual luciferase reporter gene assay. Flow cytometry, colony formation assay, Transwell assay, and MTT assay were performed to determine the cell‐cycle progression, cell apoptosis, proliferation and invasion, respectively. In addition, the tumor formation assay in nude mice was done to assess the effect of miR‐211‐5p on TC development in vivo. Results MiR‐211‐5p was underexpressed, whereas SOX 11 was overexpressed in TC . The overexpression of miR‐211‐5p inhibited the expression of SOX 11 . The cell cycle was arrested and the proliferation as well as invasiveness was suppressed by exogenous miR‐211‐5p in TC cell line. The antitumor role of miR‐211‐5p was proved by the animal experiment. Conclusion MiR‐211‐5p affected the viability, proliferation and invasion of TC by negatively regulating SOX 11 expression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here